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Abstract Crk-associated substrate (Cas) is highly phosphory-
lated by v-Src and plays a critical role in v-Src-induced cell
transformation. In this study, we found that the Src homology
(SH) 3 domain of Cas blocked v-Src-stimulated anchorage-in-
dependent cell growth, Matrigel invasion, and tumor growth in
nude mice. Biochemical analysis revealed that the Cas SH3
domain selectively inhibited v-Src-stimulated activations of
AKT and JNK, but not ERK and STAT3. Attenuation of the
AKT pathway by the Cas SH3 domain rendered v-Src-trans-
formed cells susceptible to apoptosis. Inhibition of the JNK
pathway by the Cas SH3 domain led to suppression of v-Src-
stimulated invasion. Taken together, our results indicate that
the Cas SH3 domain has an anti-tumor function, which severely
impairs the transforming potential of v-Src.
* 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
The v-src oncogene, which was ¢rst identi¢ed from the
transforming gene of Rous sarcoma virus, encodes a consti-
tutively activated form of c-Src non-receptor tyrosine kinase
[1^3]. Cell transformation by v-Src results in a wide variety of
phenotypic changes, including morphological transformation,
increase in cell migration or invasiveness, acquisition of an-
chorage and growth factor independence, and tumorigenicity
[4]. Activation of several intracellular signal transduction
pathways has been shown to be associated with transforming
potential of activated Src, such as the Ras/ERK [5], phospha-
tidylinositol 3-kinase (PI3K)/AKT [6], and STAT3/Myc [7]
pathways. Considerable evidence now indicates that elevated
expression and/or activity of Src is associated with human
cancers [8].
Crk-associated substrate (Cas) was originally identi¢ed and
cloned as a highly tyrosine-phosphorylated protein in cells
transformed by v-Src [9] or v-Crk [10]. It contains an NH2-
terminal Src homology 3 (SH3) domain, a substrate domain
that consists of 15 YXXP motifs, and a COOH-terminal Src
binding domain [11,12]. The SH3 domain of Cas could bind
proline-rich sequences of various signaling molecules such as
focal adhesion kinase (FAK [13]), guanine nucleotide ex-
change factor C3G [14], and tyrosine phosphatase PTP-
PEST [15]. Cas-de¢cient mouse embryonic ¢broblasts showed
impaired actin bundling and cell migration and were refrac-
tory to transformation by activated Src [16]. These pheno-
types were restored after re-expression of Cas, suggesting
that Cas plays essential roles in the control of the actin cyto-
skeleton organization, cell migration, and transformation
[16,17].
Cas has been demonstrated to act downstream of FAK to
promote cell migration and cell survival [18,19]. The expres-
sion of the Cas SH3 domain alone was found to inhibit FAK-
promoted cell functions by competing with endogenous Cas
for FAK binding [18,19]. Recently, we showed that the Cas
SH3 domain is able to reverse the transformed cell phenotype
induced by the synergistic e¡ect of FAK overexpression and
hepatocyte growth factor stimulation [20]. In this study, we
have examined whether the Cas SH3 domain has an inhibi-
tory e¡ect on v-Src-stimulated cell transformation.
2. Materials and methods
2.1. Materials
Matrigel was purchased from Collaborative Biomedical Products
(Bedford, MA, USA). The 24-well transwell chamber for the invasion
assay was purchased from Costar (Cambridge, MA, USA). The
monoclonal anti-FAK, anti-phosphotyrosine, anti-STAT3, anti-Bcl-
2, anti-Bad, and anti-Bcl-XL antibodies were purchased from BD
Transduction Laboratories (Lexington, KY, USA). The rabbit poly-
clonal anti-Cas (C-20), anti-Crk (C-18), anti-Src (N-16), anti-ERK
(K-23), and anti-JNK (C-17) antibodies were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). The rabbit polyclonal
anti-phosphoERK (Thr202/Tyr204), anti-phosphoJNK (Thr183/Tyr-
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185), anti-phospho-c-Jun (Ser63), anti-phosphoSTAT3 (Tyr705), anti-
AKT, anti-phosphoAKT (Ser473), anti-phosphoFKHR (Ser256), anti-
phosphoBAD (Ser136), anti-cleaved caspase 3 antibodies were pur-
chased from Cell Signaling Technology. (Beverly, MA, USA). The
rabbit polyclonal anti-phosphoSrc (Tyr416) antibody was purchased
from Biosource (Camarillo, CA, USA). The monoclonal anti-hemag-
glutinin (HA) epitope was purchased from Roche. The mouse ascites
containing monoclonal anti-Src (peptide 2^17) antibody produced by
the hybridoma (ATCC, CRL-2651) was collected in our laboratory.
The plasmid pKH3-Cas SH3 was described previously [19,20].
2.2. Cell lines and biological assays
NIH3T3 cells and v-Src-transformed NIH3T3 cells were described
previously [21] and were maintained in Dulbecco’s modi¢ed Eagle’s
medium supplemented with 10% fetal bovine serum. To generate
NIH3T3 cells or v-Src-transformed NIH3T3 cells stably expressing
HA-CasSH3, NIH3T3 cells or v-Src-transformed NIH3T3 cells were
grown on 60-mm dishes and co-transfected with 2 Wg of pKH3-
CasSH3 and 0.2 Wg of pREP3 using 10 Wl of lipofectamine following
the manufacturer’s instructions. Clones were selected in growth me-
dium containing 0.5 mg/ml G418 and 100 U/ml hygromycin and
screened by immunoblotting with anti-HA and in vitro Src activity
assay.
Soft agar colony formation assays and Matrigel invasion assays
were performed as described previously [20]. For gelatin zymography,
serum-free 36-h-conditioned medium was harvested from sub-con£u-
ent cultures. Volumes representing equivalent cell numbers were sep-
arated on a 7.5% sodium dodecyl sulfate^polyacrylamide gel electro-
phoresis (SDS^PAGE) containing 0.1% gelatin. The gel was washed
several times in Tris bu¡er (50 mM Tris, pH 7.4) containing 2.5%
(v/v) Triton X-100 at room temperature, followed by further incuba-
tion in substrate bu¡er (50 mM Tris, pH 7.4, 2.5% Triton X-100,
10 mM CaCl2, 150 mM NaCl) at 37‡C for 15 h. The gel was ¢xed
in 10% methanol and 10% acetic acid for 10 min and gelatinolytic
activity was visualized following Coomassie blue staining.
For the anoikis assay, 10-cm culture dishes were coated with 4 ml
of 1.2% poly-hydroxyethylmethacrylate (polyHEMA) in 95% ethanol.
The dishes were dried at room temperature and washed once in phos-
phate-bu¡ered saline and twice in serum-free medium. 3U106 cells in
serum-free medium were seeded on a polyHEMA-coated plate for 48
h. The cell survival rate was determined by trypan blue exclusion, as
described previously [22]. Each experiment was performed in dupli-
cate.
2.3. Tumorigenicity in nude mice
Female 5^6-week-old nude mice were subcutaneously injected in the
£ank with v-Src-transformed NIH3T3 cells or those stably expressing
HA-CasSH3. Each animal received 5U105 cells suspended in 0.2 ml
of phosphate-bu¡ered saline. Tumor volumes were measured every
other day with calipers. When tumors reach a volume of 2500^3000
mm3, mice were killed and tumors were surgically removed.
2.4. Immunoprecipitations, immunoblotting, and in vitro kinase assay
Immunocomplexes and immunoblotting were performed as de-
scribed previously [20]. To measure Src or JNK activity, anti-Src or
anti-JNK immunoprecipitates were washed three times with 1% NP-
40 lysis bu¡er and once in 20 mM Tris bu¡er. In vitro kinase reac-
tions were carried out in 40 Wl of kinase bu¡er (50 mM Tris^HCl, pH
7.5, 10 mM MnCl2) containing 10 WCi [Q-32P]ATP (3000 Ci/mmol,
NEN) and 5 Wg acid-denatured enolase (for Src) or GST-Jun (for
JNK) for 20 min at 25‡C. Reactions were terminated by the addition
of SDS sample bu¡er and proteins were resolved by SDS^PAGE.
2.5. Immuno£uorescent staining
Cells were grown on glass coverslips for 24 h prior to ¢xation in
phosphate-bu¡ered saline containing 4% paraformaldehyde at room
temperature for 30 min. Samples were permeabilized with phosphate-
bu¡ered saline containing 0.3% Triton X-100 for 30 min. Coverslips
were stained with primary antibody for 60 min and followed by goat
anti-mouse or anti-rabbit tetramethylrhodamine isothiocyanate-conju-
gated secondary antibodies (Jackson ImmunoResearch Laboratories)
at 4 Wg/ml for 60 min. Polyclonal anti-Cas (Santa Cruz Biotechnol-
ogy) and monoclonal anti-paxillin (Transduction Laboratories) anti-
bodies were diluted 1:200 before use. Fluorescein isothiocyanate
(FITC)-conjugated phalloidin (Sigma-Aldrich) at 2 WM was used to
stain actin ¢laments. Coverslips were mounted in anti-fading solution
and viewed using a Zeiss LSM laser-scanning confocal microscope.
3. Results
3.1. Expression of the Cas SH3 domain inhibits v-Src-
stimulated tyrosine phosphorylation of Cas and the
JNK pathway
HA epitope-tagged Cas SH3 domain was stably expressed
Fig. 1. The Cas SH3 domain inhibits v-Src-stimulated phosphoryla-
tion of Cas. The cell lines are designated neo for neomycin-resistant
control cells ; CasSH3 for the cells expressing the Cas SH3 domain;
v-Src for the v-Src-transformed cells; v-Src/CasSH3 for the v-Src-
transformed cells expressing the Cas SH3 domain. A: Equal
amounts of whole cell lysates (WCL) were analyzed by immunoblot-
ting (IB) with anti-HA to detect the expression of the Cas SH3 do-
main. The tyrosine phosphorylation of Cas and its associations with
Src and FAK were analyzed. B: The phosphorylation (Y416), activ-
ity, and expression of Src were analyzed. C: The tyrosine phosphor-
ylation and expression of FAK and PYK2 were analyzed. The re-
sult shown is representative of four experiments using two clones
for each cell line.
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in v-Src-transformed or normal NIH3T3 cells. To avoid clo-
nal variation, several cell clones that expressed similar levels
of v-Src and/or the Cas SH3 domain were selected for analy-
sis. In consistency with its function as a dominant-negative
version of Cas [18,19], the expression of the Cas SH3 domain
in v-Src-transformed cells markedly inhibited v-Src-stimulated
phosphorylation of Cas and its associations with Src and
FAK (Fig. 1A) without a¡ecting the activity and expression
of Src (Fig. 1B). The v-Src-stimulated tyrosine phosphoryla-
tion of FAK was not a¡ected by the Cas SH3 domain, but the
v-Src-stimulated tyrosine phosphorylation of proline-rich ty-
rosine kinase 2 (PYK2), another member in the FAK family,
was inhibited by the Cas SH3 domain (Fig. 1C).
Tyrosine-phosphorylated Cas is known to recruit the bind-
ing of the adapter protein Crk and activate the JNK pathway
[23,24]. In v-Src-transformed 3T3 cells, increased Cas phos-
phorylation coincided with increases in Crk phosphorylation,
JNK activation, and c-Jun phosphorylation (Fig. 2A). Con-
versely, inhibition of v-Src-stimulated Cas phosphorylation by
the Cas SH3 domain was concomitant with down-regulation
of those, indicating an inhibitory e¡ect of the Cas SH3 do-
main on the Cas-JNK signaling pathway. In contrast, ERK
and STAT3, both of which have been shown to be important
for v-Src’s transforming potential [25], were not a¡ected by
the Cas SH3 domain (Fig. 2B).
Fig. 2. The Cas SH3 domain inhibits v-Src-stimulated activation of
the JNK pathway. A: The tyrosine phosphorylation of Crk, the
phosphorylation and activity of JNK, and the phosphorylation of c-
Jun were analyzed. B: The phosphorylation and expression of ERK
and STAT3 were analyzed. The result shown is representative of
four experiments using two clones for each cell line.
Fig. 3. E¡ects of the Cas SH3 domain on actin cytoskeleton, Cas
localization, and focal contacts. A: Cells were stained for actin with
FITC-phalloidin and for Cas with polyclonal anti-Cas. B: Cells
were stained for actin with FITC-phalloidin and for paxillin with
monoclonal anti-paxillin. Paxillin was stained to mark the location
of focal contacts. The result shown is representative of three experi-
ments using two clones for each cell line.
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3.2. The Cas SH3 domain reverses the long spindle morphology
of the v-Src-transformed cells into a more spread cell shape
The actin cytoskeleton, localization of Cas, and focal con-
tacts were examined by £uorescent staining (Fig. 3). Paxillin, a
protein localized in focal contacts, was stained to mark the
location of focal contacts. In control NIH3T3 cells, Cas was
localized in focal contacts and organized into long parallel
¢laments with a similar distribution as actin stress ¢bers. v-
Src-transformed cells exhibited a long spindle shape and had
prominent membrane ru¥es where Cas was accumulated. Ac-
tin stress ¢bers and focal contacts were hardly detected in
those cells. The expression of the Cas SH3 domain in 3T3
cells had little e¡ect on the formation of actin stress ¢bers
and focal contacts, but it led to disappearance of Cas from
focal contacts. Importantly, the Cas SH3 domain reversed the
long spindle morphology of the v-Src-transformed cells into a
more spread cell shape, concomitant with more organized
actin cytoskeleton and increased formation of focal contacts.
Nevertheless, Cas failed to be localized in focal contacts and
showed a punctate distribution in the center of the cells (v-Src/
CasSH3) expressing both v-Src and the Cas SH3 domain.
3.3. The Cas SH3 domain blocks v-Src-stimulated tumor
growth in vivo and anchorage-independent cell growth
in vitro
To analyze the tumorigenicity of the cells, they were sub-
Fig. 4. The Cas SH3 domain blocks v-Src-stimulated tumor growth
in vivo and anchorage-independent cell growth in vitro. A: Cells
(5U105) from v-Src cells or v-Src/CasSH3 cells were subcutaneously
injected into nude mice (v-Src, n=6; v-Src/CasSH3, n=9) to mea-
sure their tumorigenicity. Two v-Src cell clones and three v-Src/
CasSH3 cell clones were used in the assay. Each clone was injected
into three mice. The size of tumor (lengthUwidthUheight) was
measured every other day with calipers. All of the mice injected
with v-Src cells formed tumors. In contrast, none of the mice in-
jected with v-Src/CasSH3 cells did. B: Cells (104) were subjected to
soft agar colony formation assay. One month later, cells were
stained and the number of colonies per 60-mm dish was counted.
The values (meansUS.E.M.) are from six data points from two ex-
periments using three clones for each cell line.
Fig. 5. The Cas SH3 domain suppresses v-Src-stimulated resistance
to apoptosis. A: Cells were grown on culture dishes in serum-free
medium or on polyHEMA-coated dishes in the medium with 10%
serum to analyze their resistance to serum deprivation and anoikis,
respectively. After 48 h, cells were collected and their survival rates
were measured by trypan blue exclusion. The values (mean-
s U S.E.M.) are from six data points from three experiments using
three clones for each cell line. B: Under the same conditions as de-
scribed for A, 48 h later, cells were lysed and equal amounts of cell
lysates were analyzed by immunoblotting with antibodies as indi-
cated. The result shown is representative of three independent ex-
periments.
FEBS 28015 13-1-04
C.-H. Cheng et al./FEBS Letters 557 (2004) 221^227224
cutaneously injected into athymic nude mice. Our results (Fig.
4A) showed that 100% of the mice (n=6) injected with v-Src-
transformed cells formed in situ solid tumors, whereas none of
the mice (n=9) injected with the v-Src/CasSH3 cells did.
Therefore, even though the catalytic activity and the expres-
sion of v-Src were not a¡ected by the Cas SH3 domain (Fig.
1B), its tumorigenicity was completely abolished by the Cas
SH3 domain. Next, the e¡ect of the Cas SH3 domain on
anchorage-independent cell growth, a hallmark of cell trans-
formation, was analyzed by soft agar colony formation assay
(Fig. 4B). Unlike v-Src cells, v-Src/CasSH3 cells hardly
formed colonies in soft agar, suggesting that the Cas SH3
domain may render v-Src-transformed cells susceptible to
anoikis, a type of apoptosis induced by the loss of cell^matrix
adhesions.
3.4. Inhibitory e¡ect of the Cas SH3 domain on
v-Src-stimulated resistance to apoptosis
To examine whether the Cas SH3 domain modulates the
sensitivity of the cells to apoptosis, the cells were grown on
culture dishes in serum-free medium or on polyHEMA-coated
dishes in the medium with 10% serum (Fig. 5A). PolyHEMA
is known to prevent matrix deposition and cell attachment
[26] and has been shown to induce anoikis [27]. After 48 h,
the cells were harvested and analyzed for their survival. Our
results showed that the resistance of v-Src-transformed 3T3
cells to serum deprivation or anoikis could be suppressed by
the Cas SH3 domain to a level similar to that of the control
cells.
The PI3K/AKT pathway has been shown to transmit sur-
vival signals for a variety of extracellular survival factors
[28,29]. We found that this pathway was constitutively acti-
vated in v-Src-transformed cells, manifested by the activation
of AKT and the phosphorylation of AKT substrates such as
FKHR and BAD. Importantly, the Cas SH3 domain appar-
ently inhibited the v-Src-stimulated activation of the pathway
(Fig. 5B). In addition, v-Src suppressed the activation of cas-
pase 3 in response to apoptotic stimuli from serum depriva-
tion or anoikis, which was partially restored by the Cas SH3
domain (Fig. 5B). The results in Fig. 5 together suggest that
the Cas SH3 domain may render v-Src-expressed cells suscep-
tible to low serum and anoikis by inhibiting v-Src-stimulated
activation of the PI3K/AKT pathway.
3.5. The Cas SH3 domain blocks v-Src-stimulated Matrigel
invasion in vitro
Increased invasiveness is another characteristic of v-Src-
transformed cells. Matrigel invasion assay was employed to
measure the invasiveness of the cells in vitro (Fig. 6A). As
expected, the ability of the v-Src/CasSH3 cells to invade Ma-
trigel was signi¢cantly (V65%) lower than that of v-Src-trans-
formed cells. Recently, FRNK, a dominant-negative version
of FAK, was shown to block v-Src-stimulated invasion by
decreasing matrix metalloproteinase-2 (MMP-2) expression
through inhibition of the Cas/JNK pathway in NIH3T3 cells
[30]. Similarly, we found that the v-Src/CasSH3 cells exhibited
decreased MMP-2 expression in comparison with v-Src-trans-
formed cells (Fig. 6B). It is possible that inhibition of v-Src-
stimulated activation of the JNK pathway by the Cas SH3
domain may account for its inhibition of invasion. Consistent
with this assumption, we found that the speci¢c JNK inhibitor
SP600125, but not the MEK inhibitor PD98059 and the PI3K
inhibitor LY294002, suppressed the invasiveness of v-Src-
transformed cells (data not shown).
4. Discussion
In this study, we have examined the e¡ect of the Cas SH3
domain on v-Src’s transforming potential by stably expressing
the Cas SH3 domain in v-Src-transformed NIH3T3 cells. Our
results demonstrate that although the Cas SH3 domain did
not a¡ect the activity and expression of v-Src (Fig. 1), it
severely impaired the transforming potential of v-Src at least
on two aspects ^ tumorigenicity (Fig. 4) and invasion (Fig. 6).
We demonstrated that inhibition of the JNK pathway by the
Cas SH3 domain or the speci¢c JNK inhibitor blocked v-Src-
stimulated invasion. On the other hand, inhibition of the
AKT pathway rendered v-Src-transformed cells susceptible
to apoptosis (Fig. 5). Our results therefore suggest that the
Cas SH3 domain selectively inhibits at least two crucial signal-
ing pathways (i.e. JNK and AKT), thereby blocking the trans-
forming potential of v-Src. It is worth noting that although
the Cas SH3 domain had a profound impact on the JNK and
AKT pathways, it had no e¡ects on v-Src-stimulated activa-
tion of ERK and STAT3 (Fig. 2), suggesting the activation of
ERK and STAT3 may not be su⁄cient for v-Src to induce cell
transformation. Nevertheless, our results do not exclude the
necessity of both in v-Src-stimulated cell transformation.
Fig. 6. The Cas SH3 domain blocks v-Src-stimulated invasion in vi-
tro. A: Cells (5U104) were subjected to Matrigel invasion assay.
The values (meansUS.E.M.) are from nine data points from three
experiments using three clones for each cell line. B: Conditioned
media collected from the indicated cells were analyzed by gelatin zy-
mography. The positions of proMMP-2 and active MMP-2 are indi-
cated. The result shown is representative of three independent ex-
periments using two clones for each cell line.
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Cas-de¢cient mouse embryonic ¢broblasts are refractory to
full transformation by activated Src, which show fewer podo-
somes and more organized actin ¢laments than those in the
control counterparts [16]. In our study, we found that the Cas
SH3 domain consistently reverses the long spindle morphol-
ogy of the v-Src-transformed cells into a more spread cell
shape in separate experiments, concomitant with more orga-
nized actin cytoskeleton and increased formation of focal con-
tacts (Fig. 3B). It is already known that the Cas SH3 domain
can function as a competitor for endogenous Cas to bind
FAK [18,19], thereby leading to less Cas localized in focal
contacts. Whether the displacement of endogenous Cas from
focal contacts by the Cas SH3 domain, as shown in Fig. 3, is
responsible for the reversion of transformed phenotypes is
unclear. However, our results strongly suggest that the Cas
SH3 domain may have a positive e¡ect on the actin cytoskel-
eton and that the reversion of v-Src-transformed cell mor-
phology may underscore observed changes in cell functions.
In fact, Cas has been reported to be important for the for-
mation of the actin stress ¢bers [16]. If the Cas SH3 domain
indeed has a positive e¡ect on the actin cytoskeleton, it could
suppress cell transformation induced by v-src or other onco-
genes through its general e¡ect on the cytoskeleton. Answers
to these questions will help us not only to understand the
function of the Cas SH3 domain on the cytoskeleton but
also to evaluate its potential use for therapeutic purposes.
Cas is highly phosphorylated in v-Src-transformed cells and
plays an essential role in v-Src-induced cell transformation
[16]. In this study, we found that Cas was prominently accu-
mulated in the membrane ru¥es of v-Src-transformed cells
(Fig. 3A). The expression of the Cas SH3 domain induced a
translocation of Cas from membrane ru¥es to the center of
the cells (Fig. 3A), concomitant with a marked (V70%) re-
duction in the v-Src-stimulated phosphorylation of Cas (Fig.
1A). This reduction is likely partial because of the inhibitory
e¡ect of the Cas SH3 domain on the association of Cas with
v-Src and FAK (Fig. 1A). FAK is known to form stable
complexes with v-Src [21]. The displacement of Cas from focal
contacts by the Cas SH3 domain may account for decreased
Cas^FAK association, thereby rendering Cas less likely to be
phosphorylated by v-Src.
Hauck et al. [30] reported that expression of FRNK, a
dominant-negative version of FAK, blocked v-Src-stimulated
invasion and metastasis by inhibiting the v-Src-stimulated
JNK pathway in v-Src-transformed NIH 3T3 cells. They dem-
onstrated that the v-Src-stimulated expression of MMP-2 is
essential for invasion, which is largely dependent on the acti-
vation of the JNK pathway. Similar to FRNK, the Cas SH3
domain blocks v-Src-stimulated invasion by decreasing MMP-
2 expression likely through its inhibition in the JNK pathway
(Fig. 6). More recently, JNK was found to directly phosphor-
ylate paxillin and promote cell motility [31], which may facil-
itate invasion as well. Unlike the Cas SH3 domain, FRNK
can only block v-Src-stimulated invasion without e¡ects on
the ability of v-Src to promote cell growth in soft agar and
tumor growth in nude mice [30]. This could be because
FRNK is a speci¢c inhibitor for FAK, and has a more speci¢c
e¡ect on intracellular signaling pathways than the Cas SH3
domain does. In fact, in addition to FAK and PYK2, several
other cellular proteins have been reported to associate with
Cas through its SH3 domain, including two protein tyrosine
phosphatases PTP1B and PTP-PEST and the guanine nucle-
otide exchange factor C3G [14,15]. Whether the Cas SH3
domain blocks v-Src-stimulated cell transformation through
its binding to any of these molecules remains to be examined.
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